Literature DB >> 25174652

Cancer drug resistance: old concept, novel solutions required.

Daniel S Peeper1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25174652      PMCID： PMC5528613          DOI： 10.1016/j.molonc.2014.07.026

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


× No keyword cloud information.
  9 in total

Review 1.  Brain metastasis: new opportunities to tackle therapeutic resistance.

Authors:  Joan Seoane; Leticia De Mattos-Arruda
Journal:  Mol Oncol       Date:  2014-06-02       Impact factor: 6.603

Review 2.  Reading between the lines; understanding drug response in the post genomic era.

Authors:  Constantine C Alifrangis; Ultan McDermott
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

3.  Cancer drug resistance: old concept, novel solutions required.

Authors:  Daniel S Peeper
Journal:  Mol Oncol       Date:  2014-08-07       Impact factor: 6.603

Review 4.  No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Authors:  Maria Romina Girotti; Grazia Saturno; Paul Lorigan; Richard Marais
Journal:  Mol Oncol       Date:  2014-08-15       Impact factor: 6.603

Review 5.  Drug resistance to targeted therapies: déjà vu all over again.

Authors:  Floris H Groenendijk; René Bernards
Journal:  Mol Oncol       Date:  2014-05-21       Impact factor: 6.603

Review 6.  Acquired and intrinsic resistance in cancer immunotherapy.

Authors:  Sander Kelderman; Ton N M Schumacher; John B A G Haanen
Journal:  Mol Oncol       Date:  2014-07-24       Impact factor: 6.603

Review 7.  Acquired resistance to EGFR-targeted therapies in colorectal cancer.

Authors:  Beth O Van Emburgh; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Salvatore Siena; Alberto Bardelli
Journal:  Mol Oncol       Date:  2014-05-14       Impact factor: 6.603

Review 8.  Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?

Authors:  Piet Borst
Journal:  Open Biol       Date:  2012-05       Impact factor: 6.411

Review 9.  Tumour heterogeneity and the evolution of polyclonal drug resistance.

Authors:  Rebecca A Burrell; Charles Swanton
Journal:  Mol Oncol       Date:  2014-07-10       Impact factor: 6.603
  9 in total
  1 in total

1.  Cancer drug resistance: old concept, novel solutions required.

Authors:  Daniel S Peeper
Journal:  Mol Oncol       Date:  2014-08-07       Impact factor: 6.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.